Articles
GLP-1s may have little to no impact on breast, thyroid cancer risk
Researchers estimate that, in 2022, about 890 million adultsTrusted Source around the world — or one in every eight — were living with obesity.
A new study published in the journal Annals of Internal Medicine provides evidence suggesting that the currently popular glucagon-like peptide-1 (GLP-1) receptor agonist medications for weight loss likely have little to no impact on a person’s obesity-related cancer risk.
Click here to access the article.